In a notable shift in the RSV vaccine landscape, Johnson & Johnson has discontinued its late-stage trial for an experimental vaccine aimed at older adults, which began in 2021. This decision, despite the vaccine showing an 80% efficacy rate in mid-stage trials, allows J&J to refocus on medicines deemed to offer greater patient benefits. The move comes as Pfizer and GSK gain FDA support for their competing vaccines, intensifying competition in a market projected to exceed $10 billion by 2030.
“Johnson & Johnson · ducked out of · the RSV vaccine race · Wednesday”
“Pfizer · duke it out with · GSK and Moderna”
“Johnson & Johnson · will discontinue · the late-stage study of its experimental respiratory syncytial virus (RSV) adult vaccine”
“Johnson & Johnson · started the global study · in 2021 in more than 27,000 adults aged 60 years and older”
“Respiratory syncytial virus (RSV) · is responsible for · 14,000 deaths in adults aged 65 and older annually in the United States”
“Pfizer and GSK · gained the backing of · a panel of U.S. Food and Drug Administration advisers · in late February and early March”
“RSV vaccine market · is estimated to be · more than $5 billion”
“RSV vaccine market · could exceed · $10 billion by 2030”
“Johnson & Johnson · was conducting · its late-stage study in more than 300 sites across the U.S., the UK, Canada, Australia, Chile, Brazil and China”
“Johnson & Johnson · plans to share · results from the late-stage study with the scientific community”
“Johnson & Johnson · showed · the vaccine was 80% effective in protecting against lower respiratory tract disease caused by RSV · positive results from a mid-stage trial”
“Johnson & Johnson's shares · were up · nearly 1% · at $153.08 on Wednesday”
